Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
Conditions: official terms
Lymphoma - Lymphoma, T-Cell
Conditions: Keywords
contiguous stage II adult diffuse large cell lymphoma, contiguous stage II adult diffuse mixed cell lymphoma, noncontiguous stage II adult diffuse large cell lymphoma, noncontiguous stage II adult diffuse mixed cell lymphoma, stage III adult diffuse large cell lymphoma, stage III adult diffuse mixed cell lymphoma, stage IV adult diffuse large cell lymphoma, stage IV adult diffuse mixed cell lymphoma, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, stage II adult T-cell leukemia/lymphoma, stage III adult T-cell leukemia/lymphoma, stage IV adult T-cell leukemia/lymphoma
Study Type
Study Phase
Phase 1/Phase 2
Study Design
Masking: Open Label, Primary Purpose: Treatment
Name: alemtuzumab Type: Biological
Name: cyclophosphamide Type: Drug
Name: doxorubicin hydrochloride Type: Drug
Name: prednisone Type: Drug
Name: vincristine sulfate Type: Drug
Name: flow cytometry Type: Other
Name: pharmacological study Type: Other
Overall Status
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from growing. Giving alemtuzumab together with combination chemotherapy may kill more cancer cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed aggressive stage II, stage III, or stage IV T-cell non-Hodgkin's lymphoma.
Detailed Description


- Establish the safety and dose-limiting toxicities of alemtuzumab in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) chemotherapy in patients with newly diagnosed, stage II-IV aggressive peripheral T-cell non-Hodgkin's lymphoma.

- Measure the pharmacokinetics of alemtuzumab using different subcutaneous doses and schedules to determine the dose with the highest achievable drug levels with acceptable toxicities worthy of further investigation.


- Determine the efficacy of alemtuzumab in combination with CHOP chemotherapy using escalating doses and 2 different drug schedules, as defined by overall response rate, progression-free survival, and overall survival.

- Measure the effects of this regimen on T-cell reconstitution and cytomegalovirus reactivation.

OUTLINE: This is a multicenter, phase I, dose-escalation study of alemtuzumab followed by an open-label, phase II study.

- Phase I: Patients receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Patients also receive alemtuzumab subcutaneously (SC) on day 1 OR on days 1, 8, and 15. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of alemtuzumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

- Phase II: Patients receive CHOP chemotherapy and alemtuzumab (at the MTD determined in phase I) as in phase I (on the most effective regimen).

Patients undergo blood collection at baseline, periodically during study treatment, and after completion of study treatment for pharmacokinetics and other correlative studies. Samples are examined for presence of cytomegalovirus antigen and by flow cytometry for B- and T-cell quantification.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 84 patients will be accrued for this study.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both

- Histologically confirmed aggressive peripheral T-cell non-Hodgkin's lymphoma (NHL), including the following nodal or extranodal subtypes:

- Nodal:

- Angioimmunoblastic lymphadenopathy

- ALK 1-negative anaplastic large cell NHL

- Peripheral T-cell lymphoma not otherwise specified

- Extranodal:

- Hepatosplenic NHL

- Enteropathy-associated NHL

- Panniculitic NHL

- Stage II-IV disease

- Newly diagnosed, CD52+ disease

- Measurable or evaluable disease

- No known CNS involvement with lymphoma

- No nasal natural killer T-cell NHL


- ECOG performance status 0-2

- Life expectancy > 4 months

- Absolute neutrophil count ≥ 1,000/mm³*

- Platelet count ≥ 75,000/mm³*

- Hemoglobin ≥ 8.5 g/dL*

- Bilirubin < 2.0 mg/dL

- Alkaline phosphatase ≤ 2 times upper limit of normal (ULN)

- AST or ALT < 2 times ULN

- Creatinine < 1.5 mg/dL*

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No known hypersensitivity to any of the study drugs

- No serious illnesses that would preclude compliance with study requirements

- No known HIV positivity

- No other preexisting immunodeficiency (e.g., post-organ transplant)

- No other malignancy within the past 5 years except cervical carcinoma in situ or nonmelanoma skin cancer NOTE: *Unless directly attributable to NHL


- No prior chemotherapy or radiotherapy

- Up to 7 days of prednisone preceding initiation of chemotherapy allowed

- No other concurrent chemotherapy, radiotherapy, or immunotherapy

- No other concurrent corticosteroids except dexamethasone used as an antiemetic for a brief period
St. Paul's Hospital at Providence Health Care - Vancouver
Vancouver, British Columbia, Canada
Status: Recruiting
Contact: Contact Person - 604-806-9656
Margaret and Charles Juravinski Cancer Centre
Hamilton, Ontario, Canada
Status: Recruiting
Contact: Graeme Fraser, MD, FRCPC - 905-575-7820
London Regional Cancer Program at London Health Sciences Centre
London, Ontario, Canada
Status: Recruiting
Contact: Joy Mangel, MD - 519-685-8615 -
Odette Cancer Centre at Sunnybrook
Toronto, Ontario, Canada
Status: Recruiting
Contact: Rena Buckstein, MD - 416-480-5847 -
Princess Margaret Hospital
Toronto, Ontario, Canada
Status: Recruiting
Contact: Michael R. Crump, MD, FRCPC - 416-946-4567 -
Start Date
September 2006
Odette Cancer Centre at Sunnybrook
National Cancer Institute (NCI)
Record processing date processed this data on July 28, 2015 page